Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 224

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 224
---
 Transactions

In November 2022, the Company issued 100 shares of the Company’s common stock for an aggregate purchase price of $10 to Chris Kim, the Company’s Chief Executive Officer. Such shares on the date of issuance were duly and validly authorized and issued. Each outstanding share of stock has voting power equal to one vote on each matter submitted at any stockholder’s meeting. As of the date of these consolidated financial statements, no consideration has been received from Mr. Kim for the issuance of these shares. Accordingly, the Company has recorded a “Stock subscription receivable” within the stockholder’s equity section on its consolidated balance sheet as of December 31, 2024 and 2023.

<div align='center'>F-17</div>

Note 4. Commitments and Contingencies

The Company is not apartyto any material legal proceedings and is not aware of any material pending or threatened claims.The Company does not have any commitments as of December 31, 2024 and 2023.

Note 5. Subsequent Events

The Company has completed an evaluation of all subsequent events through the date of this filing to ensure that these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. No subsequent events were identified other than the closing of the Business Combination, as discussed Note 1.

<div align='center'>F-18</div>

LIMINATUS PHARMA, LLC CONDENSED BALANCE SHEETS (in thousands)

| ​                                       
 ​                                       | ​ | ​              
 March 31, 2025 |          ​ | ​ | ​                 
 December 31, 2024 |       ​ |
|:----------------------------------------|:--|:---------------|-----------:|:--|:------------------|--------:|
| ​                                       | ​ | ​              | -Unaudited | ​ | ​                 |       ​ |
| ASSETS                                  | ​ |                |          ​ | ​ |                   |       ​ |
| Current assets:                         |   | ​              |            |   | ​                 |         |
| Cash                                    | ​ | $              |         35 | ​ | $                 |      56 |
| Loan receivable                         | ​ |                |      4,244 | ​ |                   |   3,669 |
| Deferred transaction costs              | ​ |                |      1,513 | ​ |                   |   1,401